Samsung Bioepis Adds To Biogen Collaboration
New Deal Covers ‘Next-Generation’ Biosimilars Ranibizumab And Aflibercept
Samsung Bioepis and Biogen have agreed a marketing deal for ‘next generation’ biosimilars aflibercept and ranibizumab in the US, Canada, Europe, Japan and Australia, as well as providing an option for Biogen to extend its existing deal to market anti-TNF biosimilars adalimumab, etanercept and infliximab in Europe and adding a further option for rights to sell these three biosimilars in China.
You may also be interested in...
Samsung Bioepis and Biogen have come in with a hefty discount as they mark a major milestone by launching their Byooviz biosimilar ranibizumab rival to Lucentis in the US.
Samsung Bioepis has racked up a further endorsement for its Byooviz biosimilar ranibizumab, after Health Canada approved the rival to Lucentis.
With the first approved rival to Lucentis in both the EU and US, Samsung Bioepis is laying the groundwork for biosimilars to break into ophthalmology ahead of launching its Byooviz version of ranibizumab, explains vice-president of commercial strategy Josh Lee.